Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

2.

Engelberts

PJ

,

Hiemstra

IH

,

de Jong

B

, et al.

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

.

EBioMedicine

.

2020

;

52

:

102625

.

3.

Bacac

M

,

Colombetti

S

,

Herter

S

, et al.

CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies

.

Clin Cancer Res

.

2018

;

24

(

19

):

4785

-

4797

.

4.

Falchi

L

,

Vardhana

SA

,

Salles

GA

.

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

.

Blood

.

2023

;

141

(

5

):

467

-

480

.

5.

Budde

LE

,

Sehn

LH

,

Matasar

M

, et al.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

.

Lancet Oncol

.

2022

;

23

(

8

):

1055

-

1065

.

6.

Budde

LE

,

Assouline

S

,

Sehn

LH

, et al.

Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study

.

J Clin Oncol

.

2022

;

40

(

5

):

481

-

491

.

7.

Dickinson

MJ

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

387

(

24

):

2220

-

2231

.

8.

Hutchings

M

,

Morschhauser

F

,

Iacoboni

G

, et al.

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

.

J Clin Oncol

.

2021

;

39

(

18

):

1959

-

1970

.

9.

Thieblemont

C

,

Phillips

T

,

Ghesquieres

H

, et al.

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

.

J Clin Oncol

.

2023

;

41

(

12

):

2238

-

2247

.

10.

Schaff

LR

,

Grommes

C

.

Primary central nervous system lymphoma

.

Blood

.

2022

;

140

(

9

):

971

-

979

.

11.

Ferreri

AJM

,

Doorduijn

JK

,

Re

A

, et al.

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

.

Lancet Haematol

.

2021

;

8

(

2

):

e110

-

e121

.

12.

Rubenstein

JL

,

Combs

D

,

Rosenberg

J

, et al.

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

.

Blood

.

2003

;

101

(

2

):

466

-

468

.

13.

Batchelor

TT

,

Grossman

SA

,

Mikkelsen

T

,

Ye

X

,

Desideri

S

,

Lesser

GJ

.

Rituximab monotherapy for patients with recurrent primary CNS lymphoma

.

Neurology

.

2011

;

76

(

10

):

929

-

930

.

14.

Herter

S

,

Herting

F

,

Mundigl

O

, et al.

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models

.

Mol Cancer Ther

.

2013

;

12

(

10

):

2031

-

2042

.

15.

DeFilipp

Z

,

Li

S

,

El-Jawahri

A

, et al.

High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission

.

Cancer

.

2017

;

123

(

16

):

3073

-

3079

.

16.

Chen

Y Bin

,

Batchelor

T

,

Li

S

, et al.

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

.

Cancer

.

2015

;

121

(

2

):

226

-

233

.

17.

Rubenstein

JL

,

Fridlyand

J

,

Abrey

L

, et al.

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma

.

J Clin Oncol

.

2007

;

25

(

11

):

1350

-

1356

.